Natco Pharma Ltd
NATCOPHARMNatco Pharma Ltd
NATCOPHARM
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 17.08 | 4.86 | 0.73% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 46.01 | 6.09 | 0.55% |
Forecast & Ratings
Detailed Forecast from 12 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Natco Pharma Limited is a research and development (R&D)-focused pharmaceutical company. The Company is engaged in developing, manufacturing and marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs).
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Zydus Lifesciences Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,054.10 | 2,034.10 | 2,225.20 | 2,224.70 | 2,022.40 | 2,155.70 | 2,043.80 | 2,811.70 | 4,126.90 | 4,126.90 | ||||||||||
Raw Materials | 318.90 | 617.90 | 436.40 | 388.10 | 456.80 | 559.50 | 577.70 | 651.00 | 2,247.40 | 2,247.40 | ||||||||||
| Power & Fuel Cost | 43.70 | 50.50 | 56.20 | 59.60 | 62.40 | 61.10 | 76.40 | 81.90 | ||||||||||||
| Employee Cost | 179.80 | 243.20 | 325.60 | 355.90 | 375.00 | 414.90 | 444.80 | 486.70 | ||||||||||||
| Selling & Administrative Expenses | 180.90 | 299.60 | 304.50 | 351.10 | 311.60 | 300.90 | 367.70 | 388.80 | ||||||||||||
| Operating & Other expenses | 53.40 | 125.60 | 133.70 | 145.00 | 126.60 | 109.50 | 214.70 | 163.10 | ||||||||||||
EBITDA | 277.40 | 697.30 | 968.80 | 925.00 | 690.00 | 709.80 | 362.50 | 1,040.20 | 1,879.50 | 1,879.50 | ||||||||||
| Depreciation/Amortization | 50.80 | 54.40 | 66.20 | 81.00 | 99.80 | 116.90 | 142.60 | 163.80 | 186.80 | 186.80 | ||||||||||
| PBIT | 226.60 | 642.90 | 902.60 | 844.00 | 590.20 | 592.90 | 219.90 | 876.40 | 1,692.70 | 1,692.70 | ||||||||||
| Interest & Other Items | 22.90 | 18.50 | 15.40 | 19.30 | 21.50 | 13.30 | 17.70 | 14.50 | 19.20 | 19.20 | ||||||||||
| PBT | 203.70 | 624.40 | 887.20 | 824.70 | 568.70 | 579.60 | 202.20 | 861.90 | 1,673.50 | 1,673.50 | ||||||||||
| Taxes & Other Items | 46.60 | 138.40 | 191.00 | 180.30 | 107.90 | 138.70 | 32.20 | 146.60 | 285.20 | 285.20 | ||||||||||
| Net Income | 157.10 | 486.00 | 696.20 | 644.40 | 460.80 | 440.90 | 170.00 | 715.30 | 1,388.30 | 1,388.30 | ||||||||||
| EPS | 9.23 | 27.89 | 38.81 | 35.09 | 25.26 | 24.20 | 9.32 | 39.22 | 77.34 | 76.08 | ||||||||||
| DPS | 1.25 | 6.75 | 8.25 | 6.25 | 6.75 | 5.25 | 4.50 | 5.50 | 9.50 | 9.50 | ||||||||||
| Payout ratio | 0.14 | 0.24 | 0.21 | 0.18 | 0.27 | 0.22 | 0.48 | 0.14 | 0.12 | 0.12 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Natco Pharma Ltd | 17.08 | 4.86 | 0.73% |
| Sun Pharmaceutical Industries Ltd | 41.74 | 5.96 | 0.81% |
| Zydus Lifesciences Ltd | 31.44 | 5.49 | 0.25% |
| Cipla Ltd | 29.39 | 5.11 | 0.87% |
Price Comparison
Compare NATCOPHARM with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Increased Total Retail Holding
In last 3 months, retail holding in the company has increased by 1.02%
Increased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has increased by 1.31%
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Decreased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has decreased by 1.41%
Top 5 Mutual Funds holding Natco Pharma Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
TATA MUTUAL FUND EQ P/E DIRECT GROWTH OPEN ENDED Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.5967% | Percentage of the fund’s portfolio invested in the stock 1.67% | Change in the portfolio weight of the stock over the last 3 months 0.72% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 28/52 (+13) |
Tata Small Cap Fund-Direct Plan-Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.4429% | Percentage of the fund’s portfolio invested in the stock 1.33% | Change in the portfolio weight of the stock over the last 3 months -0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 36/55 (-1) |
SBI FUNDS MANAGEMENT PVT LTD#SBI MF-SBI MAGNUM MIDCAP FUND DIRECT PL GROWTH Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.3694% | Percentage of the fund’s portfolio invested in the stock 0.43% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 32/86 (-1) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
Dividend Yield
Current dividend yield is 0.73%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹7.31 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateFeb 26, 2024
Dividend/Share
₹1.25
Ex DateEx Date
Feb 26, 2024
Cash Dividend
Ex DateEx DateNov 24, 2023
Dividend/Share
₹1.25
Ex DateEx Date
Nov 24, 2023
Cash Dividend
Ex DateEx DateAug 22, 2023
Dividend/Share
₹7.00
Ex DateEx Date
Aug 22, 2023
Cash Dividend
Ex DateEx DateFeb 21, 2023
Dividend/Share
₹1.25
Ex DateEx Date
Feb 21, 2023
Cash Dividend
Ex DateEx DateNov 21, 2022
Dividend/Share
₹0.75
Ex DateEx Date
Nov 21, 2022
Natco Pharma announced that Sanivarapu Ravi Prakash Reddy, Senior Vice President - Operations, Pharma Division, Kothur, Rangareddy District, Telangana has resigned and relieved w.e.f. 25 July 2024. Powered by Capital Market - Live
Natco Pharma will hold a meeting of the Board of Directors of the Company on 12 August 2024.Powered by Capital Market - Live
Natco Pharma Ltd soars 0.97%, up for fifth straight session
Natco Pharma Ltd gained for a fifth straight session today. The stock is quoting at Rs 1336.7, up 0.97% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 1.28% on the day, quoting at 24718.65. The Sensex is at 80971.98, up 1.16%. Natco Pharma Ltd has risen around 16.11% in last one month. Meanwhile, Nifty Pharma index of which Natco Pharma Ltd is a constituent, has risen around 10% in last one month and is currently quoting at 21105.5, up 1.71% on the day. The volume in the stock stood at 4.18 lakh shares today, compared to the daily average of 10.44 lakh shares in last one month.The PE of the stock is 18.15 based on TTM earnings ending March 24.Powered by Capital Market - Live
Natco Pharma Ltd rises for third consecutive session
Natco Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 1277.85, up 1.43% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.56% on the day, quoting at 24341.6. The Sensex is at 79865.77, down 0.7%. Natco Pharma Ltd has risen around 7.12% in last one month. Meanwhile, Nifty Pharma index of which Natco Pharma Ltd is a constituent, has risen around 6.84% in last one month and is currently quoting at 20755.35, up 0.55% on the day. The volume in the stock stood at 4.3 lakh shares today, compared to the daily average of 9.91 lakh shares in last one month.The PE of the stock is 17.27 based on TTM earnings ending March 24.Powered by Capital Market - Live
Natco Pharma and 4 other stocks closed above VWAP
LTIMindTree, Bajaj Finserv, Natco Pharma & Bikaji Foods: These are 4 stock picks from SMC Global
Natco Pharma Ltd spurts 5.12%, rises for fifth straight session
Brokerage Views: Motilal Oswal, Citi On LIC, Nuvama On Natco Pharma And More
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 13.15%, vs industry avg of 8.96%
Increasing Market Share
Over the last 5 years, market share increased from 0.98% to 1.12%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 16.59%, vs industry avg of 15.15%